Elacestrant Impresses in EMERALD Trial of Breast Cancer

$ 16.00

4.6
(461)
In stock
Description

Experts Discuss Clinical Highlights from SABCS 2021

Elacestrant Impresses in EMERALD Trial of Breast Cancer

May 30 - June 3, 2014 Chicago, Illinois - ppt download

LANDMARK TRIALS IN BREAST CANCER

EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer

Oncology Brothers on X: 3. #EMERALD trial for #Elacestrant HR+ mESR1 advanced breast CA -median PFS was 3.8 month - Common AE: musculoskeletal pain, nausea, increased cholesterol #bcsm

Elacestrant in management of ER-Positive, HER2-Negative BC

J.P. Morgan 2022 Conference Review, PDF, Novartis

Breast landmark trials dr.kiran